Phase 2 Evidence and Impact Analysis
Article 1 — Universal CAR-T cell therapy (PMID 42924291)
Narrative review | T6: Novel therapeutics | triage_score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Synthesizes rapidly evolving allogeneic CAR-T engineering landscape; genome-editing strategies well-catalogued but the integration of clinical trial data with translational barrier mapping adds meaningful synthesis value |
| Clinical Relevance | 6 | High conceptual relevance; allogeneic CAR-T remains pre-practice-changing — durability and immune rejection unsolved; review cannot itself change practice |
| Population Reach | 8 | Hematologic malignancies + solid tumor pipeline; if allogeneic CAR-T becomes scalable, global access to cellular immunotherapy could expand dramatically |
| Implementation Speed | 3 | Key biological hurdles (persistence, host rejection) unresolved; 5–10+ years to broad clinical adoption |
| Evidence Strength | 3 | Narrative review — no primary data, no meta-analytic synthesis; selection bias in reviewed literature possible |
Key quantitative result: None — narrative synthesis only; no pooled effect sizes
External validation: Not applicable (review)
Main limitation: Narrative review format; no systematic search reported; synthesis reflects authors' framing of a contested, fast-moving field
Equity implications: The core promise of allogeneic CAR-T is democratization — eliminating per-patient manufacturing reduces cost barriers disproportionately affecting LMICs and patients without the health/time to wait for autologous manufacturing. However, HLA-engineering complexities may create new population-specific matching issues
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 2 — Liquid biopsy in pancreatic ductal adenocarcinoma (PMID 42921021)
Narrative review | T3: Early cancer detection | triage_score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Intended-use framework across six scenarios is a genuinely useful conceptual contribution; individual biomarker findings are not new, but the structured deployment logic adds clinical clarity |
| Clinical Relevance | 7 | PDAC is the highest-unmet-need solid tumor for early detection; the framework directly guides clinical decision-making on where liquid biopsy adds value now vs. where it shouldn't yet be deployed |
| Population Reach | 7 | ~500,000 new PDAC cases annually worldwide; 5-year survival ~12%; even modest early detection improvement translates to thousands of lives |
| Implementation Speed | 3 | ctDNA in post-surgical monitoring is implementable now; population screening remains years away pending prospective validation trials |
| Evidence Strength | 3 | Narrative review; no primary data or meta-analytic pooling; conclusions appropriately cautious but unsupported by systematic literature grading |
Key quantitative result: No pooled estimates; conceptual framework rather than diagnostic performance synthesis
External validation: Not applicable (review)
Main limitation: Narrative design without systematic methodology; heterogeneous underlying studies; no PROSPERO registration noted
Equity implications: PDAC disproportionately affects older adults and has worse outcomes in lower-income populations with limited access to specialty care; liquid biopsy could benefit these groups most if blood-based testing becomes accessible — but current multimodal AI assays are expensive and concentrated in high-income centers
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 3 — Dapagliflozin in HFpEF (PMID 42923614)
Retrospective cohort study | T7: Cardiovascular-metabolic | triage_score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | SGLT2 inhibitors in HFpEF are supported by DELIVER trial; this adds mechanistic detail (cytokine panel, E/e' ratio, LAVI) at a smaller scale — incremental rather than paradigm-shifting |
| Clinical Relevance | 7 | HFpEF is highly prevalent with few proven pharmacological options; the specific cytokine and diastolic function findings provide mechanistic support for a clinically deployable drug; aligns with evolving guidelines |
| Population Reach | 9 | HFpEF accounts for ~50% of heart failure cases globally; estimated 30–40 million patients worldwide with few proven drug options |
| Implementation Speed | 7 | Dapagliflozin already approved and available; findings could immediately inform prescribing decisions for HFpEF patients in practice |
| Evidence Strength | 5 | Retrospective cohort, n=114, 6-month follow-up; no randomization; confounding by indication possible; standard care comparison group not well characterized; single-center presumed |
Key quantitative result: E/e' improved 14.8→12.1; NT-proBNP reduced 28.4%; IL-6, TNF-α, hs-CRP reduced; Minnesota LHFQ improved vs. standard care
External validation: Not independently validated; requires prospective RCT confirmation
Main limitation: Retrospective design with high risk of confounding; small sample; follow-up limited to 6 months; standard-care group composition unclear
Equity implications: HFpEF disproportionately affects women, elderly, and Black populations; dapagliflozin is widely available generically in many markets, reducing cost-access barriers vs. novel agents — moderate equity benefit
Evidence Maturity (revised): Validated → downgrade to Exploratory-to-Validated transition (the DELIVER RCT validates the drug class; this study is confirmatory/mechanistic, not independently practice-changing)
Article 4 — Tirzepatide and beta-cell function systematic review (PMID 42923463)
Systematic review | T7: Cardiovascular-metabolic | triage_score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dual GIP/GLP-1 agonism mechanism is established; aggregating beta-cell function outcomes into a systematic synthesis with comparative data vs. semaglutide and dulaglutide provides useful quantitative framing |
| Clinical Relevance | 7 | Beta-cell preservation/restoration is the holy grail of T2DM management; disease-modification framing could influence treatment sequencing and payer coverage decisions |
| Population Reach | 9 | ~537 million people globally with T2DM; tirzepatide is already marketed — this evidence applies immediately to an enormous treated population |
| Implementation Speed | 8 | Tirzepatide in clinical use; beta-cell data could shift prescribing preferences toward earlier use — no new regulatory hurdles required |
| Evidence Strength | 5 | Systematic review methodology but evidence base predominantly industry-funded post-hoc analyses; publication bias highly probable; 8 reports, n=3,442 — adequate size but methodological quality of source studies is variable |
Key quantitative result: HOMA2-B +77–163%; disposition index ~6-fold increase; fasting proinsulin −55%; C-peptide ratio −49% vs. baseline
External validation: No independent academic replication yet; all studies traced to SURPASS program
Main limitation: Industry funding concentration; post-hoc analysis design in source studies; no long-term beta-cell durability data; no dose-response characterization
Equity implications: Tirzepatide is currently premium-priced; beta-cell benefits may be most meaningful for patients treated early in the disease course — those with better insurance access. This creates an equity concern if disease modification is confirmed
Evidence Maturity (revised): Validated ✓ (confirmed, with caveat on industry bias)
Article 5 — Idiopathic pulmonary hemosiderosis systematic review (PMID 42923410)
Systematic review, PROSPERO registered | T9: Rare diseases | triage_score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First comprehensive PROSPERO-registered systematic review of IPH treatment; synthesizes 149 studies across 494 children — this is definitive-level evidence for a disease where none existed |
| Clinical Relevance | 7 | No approved therapy for IPH; the rituximab signal and relapse rate quantification directly guide clinical management and trial design; mortality data are alarming and galvanizing |
| Population Reach | 4 | Extremely rare disease (incidence ~0.24–1.23/million); but relative to the relevant clinical population (children with no approved therapy), impact is very high. Scored relative to unmet need |
| Implementation Speed | 5 | Rituximab is available; off-label use could be informed by this synthesis; but evidence quality for rituximab remains case-series level — prospective trials needed before standard adoption |
| Evidence Strength | 6 | PROSPERO registration adds rigor; systematic search across 149 studies with 494 children is the largest available synthesis; limited by rarity-driven case-series dominance in source studies |
Key quantitative result: Corticosteroids first-line in 78.7%; relapse 35–60%; rituximab emerging steroid-sparing; mortality 27.3% in one cohort
External validation: No prior systematic review of equivalent scope — this is the external reference going forward
Main limitation: Underlying evidence is case series and small cohorts; no RCT exists or is feasible given rarity; geographic concentration of cases
Equity implications: Children in LMICs face worst outcomes due to delayed diagnosis and limited rituximab access; the review's urgency call for multicenter studies must include geographically diverse sites
Evidence Maturity (revised): Validated ✓ (confirmed; strongest possible synthesis for this rarity level)
Article 6 — Garsorasib + pembrolizumab + chemotherapy in KRAS G12C NSCLC (PMID 42924167)
Phase 1b clinical trial | T6: Novel therapeutics | triage_score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | KRAS G12C inhibition is a validated concept (sotorasib, adagrasib approved); combining with pembrolizumab + platinum doublet is the frontier question — this is a meaningful negative data point in that space |
| Clinical Relevance | 7 | Negative trial result with direct pipeline consequence — removes this combination from further development; redirects research toward dose-modified or doublet (not triplet) approaches for KRAS G12C NSCLC |
| Population Reach | 6 | KRAS G12C in |
| Implementation Speed | 4 | Negative finding accelerates elimination of this regimen; redirects to alternative combinations; timeline for next-generation strategy unclear |
| Evidence Strength | 7 | Phase 1b with 17 patients is small but fit-for-purpose for the safety signal question; the 94% grade 3+ AE rate is decisive; not proceeding to Phase 2 is a definitive clinical signal |
Key quantitative result: ORR 59%; mPFS 7.4 months; grade 3+ AEs in 94%; dose modifications in 88%; trial terminated — did not advance to Phase 2
External validation: Consistent with emerging toxicity signals from other KRAS G12C + ICI combinations
Main limitation: n=17 — too small for efficacy conclusions; no control arm; single regimen tested
Equity implications: Neutral — negative finding applies broadly. Redirects resources toward safer KRAS G12C combinations
Evidence Maturity (revised): Validated ✓ (confirmed; Phase 1b level for safety determination)
Article 7 — cfDNA for oral cancer in Sub-Saharan Africa (PMID 42920974)
Narrative review | T3: Early cancer detection | triage_score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | The geographic reframing (SSA-specific barriers) is the novel contribution; cfDNA for OSCC is not new but SSA population-specific analysis is underrepresented in the literature |
| Clinical Relevance | 5 | Important equity signal but no new diagnostic evidence generated; clinical implementation requires population-specific validation not yet performed |
| Population Reach | 6 | SSA carries a rising oral cancer burden; 1.1 billion people in SSA, with oral cancer disproportionately affecting lower-SES populations — high if validation follows |
| Implementation Speed | 2 | Infrastructure, training, and population-specific database development needed before clinical use; 5–10+ year horizon |
| Evidence Strength | 2 | Narrative review only; no primary data; highly exploratory |
Main limitation: No primary data; review of evidence generated in non-SSA populations applied to SSA context
Equity implications: This article is fundamentally about equity — current liquid biopsy evidence excludes SSA populations and may not translate; the call for SSA-specific validation is the core contribution
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 8 — AI fungal detection (YOLOv11) (PMID 42923083)
Comparative study, prospective specimens | T4: AI diagnostics | triage_score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | YOLO-series benchmarking in mycology is specific and useful; the optimized IoU threshold finding and online platform deployment add practical novelty |
| Clinical Relevance | 6 | Dermatology/mycology diagnostic support with demonstrated deployment; replaces subjective microscopy interpretation — moderate clinical impact in settings with limited mycology expertise |
| Population Reach | 5 | Superficial fungal infections affect ~25% of the world's population; AI diagnostic support most impactful in resource-limited settings without expert mycologists |
| Implementation Speed | 7 | Platform already deployed online; integration into laboratory workflows is feasible near-term; regulatory pathway for diagnostic software support is shorter than therapeutic approval |
| Evidence Strength | 6 | Prospective patient specimens (n=1,730); multi-model comparison with optimization; limitation is single-center derivation and absence of prospective clinical-outcome validation |
Key quantitative result: YOLOv11 F1 = 97.84% for fungal hyphae detection
Main limitation: Single-center derivation; no prospective clinical validation (impact on diagnostic accuracy in practice, misdiagnosis rates, workflow outcomes)
Equity implications: High equity potential — automated microscopy for fungal infections could benefit LMICs where expert mycologists are unavailable
Evidence Maturity (revised): Validated ✓ (confirmed; strong technical validation, clinical validation pending)
Article 9 — RAS pathway mutations in colorectal cancer (WES cohort) (PMID 42921908)
Cohort study, whole-exome sequencing | T5: Precision oncology | triage_score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | RAS pathway in CRC is well-characterized; ethnic disparities in BRAF V600E frequency are the novel finding; KRAS G12C prevalence confirmation in a multi-ethnic NCI cohort adds precision oncology value |
| Clinical Relevance | 6 | 3.1% KRAS G12C prevalence defines the sotorasib-eligible CRC population; BRAF disparity finding has implications for treatment access equity across ethnicities |
| Population Reach | 8 | CRC is the 3rd most common cancer globally; ~150,000 new US cases/year — 3.1% KRAS G12C represents ~4,650 newly targetable US patients annually |
| Implementation Speed | 6 | KRAS G12C inhibitors already in clinical use for CRC; prevalence data immediately inform patient selection; ethnic disparity finding requires practice change |
| Evidence Strength | 7 | Multi-institutional NCI-funded WES of n=1,243 paired tumor-normal samples; robust design; multi-ethnic; limitation is survival data without treatment-stratified analysis |
Key quantitative result: KRAS G12C 3.1%; any RAS mutation 40.8%; KRAS-PIK3CA co-mutation 10.1%; lower BRAF V600E in Hispanic patients
Main limitation: No treatment-stratified survival analysis; cross-sectional mutation profiling without longitudinal outcomes; survival analysis shows RAS status not independently associated with OS after adjustment — limits clinical prognostic utility
Equity implications: Hispanic patients show lower BRAF V600E — this has direct implications for cetuximab eligibility and access; if confirmed, may require ethnicity-aware mutation testing protocols
Evidence Maturity (revised): Validated ✓ (confirmed)
Article 10 — SGLT2 inhibitors and exercise in diabetic kidney disease (PMID 42923500)
Narrative review | T7: Cardiovascular-metabolic | triage_score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Mechanistic rationale for combining SGLT2i + exercise is plausible and well-argued; lack of clinical RCT data limits novelty beyond hypothesis generation |
| Clinical Relevance | 5 | Relevant to a large population; but without RCT evidence of combined superiority, clinical translation is limited to lifestyle counseling reinforcement |
| Population Reach | 8 | DKD affects |
| Implementation Speed | 3 | Combined RCTs not yet done; clinical guidance cannot change without that evidence |
| Evidence Strength | 2 | Narrative review; no primary or meta-analytic data |
Main limitation: No clinical trial data on combined SGLT2i + exercise; mechanistic plausibility does not confirm additive or synergistic clinical benefit
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 11 — Brain care score and structural brain changes (PMID 42922092)
Cross-sectional | T8: Aging | triage_score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Brain care score as a composite is being validated against MRI markers — incremental contribution; white matter and hippocampal volume associations with modifiable risk factors are not new |
| Clinical Relevance | 6 | Actionable — score composed of modifiable factors; if validated longitudinally, could guide brain-health clinical counseling |
| Population Reach | 8 | Cognitive decline and dementia affect tens of millions globally; modifiable risk factor interventions have population-wide reach |
| Implementation Speed | 5 | Score is simple and cheap to administer; but cross-sectional evidence limits causal interpretation needed for clinical recommendation |
| Evidence Strength | 4 | Large cohort but cross-sectional design; cannot establish directionality; medium classification confidence noted; no DOI available |
Main limitation: Cross-sectional — cannot determine whether better brain care scores causally protect brain structure or whether healthier people score higher
Evidence Maturity (revised): Validated → Exploratory-to-Validated (association established; causality unconfirmed; medium classification confidence applies conservative scoring)
Article 12 — Traditional Chinese medicines for ALS (Bayesian NMA) (PMID 42923269)
Bayesian network meta-analysis | T9: Rare diseases | triage_score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Bayesian NMA methodology is appropriate; TCM for ALS is a niche area; global clinical novelty is limited by geographic restriction of the evidence base |
| Clinical Relevance | 4 | Relevant within Chinese healthcare context; limited generalizability to Western or global populations; ALS treatment options are desperately needed but this evidence doesn't translate directly |
| Population Reach | 4 | ALS affects ~5/100,000 globally; evidence applicable primarily within TCM-using populations |
| Implementation Speed | 4 | TCM interventions are available in relevant markets; but quality evidence for non-TCM populations is absent |
| Evidence Strength | 5 | NMA is the highest-available evidence design for this question; limited by RCT quality heterogeneity and geographic concentration; medium classification confidence |
Main limitation: RCT quality variable; evidence almost entirely from Chinese-context studies; non-Chinese populations may have different responses and access
Evidence Maturity (revised): Validated ✓ (confirmed, with geographic caveat)
Article 13 — CRS+HIPEC in pseudomyxoma peritonei, 15-year outcomes (PMID 42922069)
Retrospective cohort, 15-year single-center | T9: Rare diseases | triage_score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CRS+HIPEC is established for PMP; long-term single-center outcome data adds to the literature but is not conceptually new |
| Clinical Relevance | 6 | Benchmark outcome data for a rare cancer with no systemic therapy alternative; directly informs surgical decision-making and patient counseling |
| Population Reach | 3 | Extremely rare (~2/million/year); high within-disease clinical relevance |
| Implementation Speed | 6 | Standard-of-care approach; outcomes data reinforces current practice rather than changing it |
| Evidence Strength | 5 | 15-year longitudinal depth is valuable; single-center retrospective limits generalizability; medium classification confidence |
Main limitation: Single-center; retrospective; no comparison arm against systemic therapy (which doesn't exist — appropriate)
Evidence Maturity (revised): Validated ✓ (confirmed)
Article 14 — GAS2L3 prognostic model in multiple myeloma (PMID 42923674)
Bioinformatics + cell line | T1: Hematologic malignancies | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | GAS2L3 is not well characterized in MM; HLA-E/KLRK1 immune axis connection adds mechanistic novelty |
| Clinical Relevance | 3 | Cell line and GEO dataset study; no patient outcome validation; ≥5 years from clinical translation |
| Population Reach | 6 | MM affects ~160,000 new cases/year globally |
| Implementation Speed | 2 | Early discovery; preclinical only |
| Evidence Strength | 3 | GEO dataset + cell line; no clinical patient cohort validation; LASSO models from public datasets are hypothesis-generating only |
Main limitation: No clinical cohort validation; GEO data may not reflect current treatment landscapes; cell line results may not translate
Evidence Maturity (revised): Exploratory ✓ (confirmed); non-human component caps Clinical Relevance
Article 15 — PHLPP2 in multiple myeloma (PMID 42923862)
Translational study, n=16 | T1: Hematologic malignancies | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | PHLPP2 downregulation in MM adds to the phosphatase regulatory landscape; R-ISS correlation is a useful clinical anchor |
| Clinical Relevance | 3 | Tiny sample (n=16); no functional or mechanistic validation beyond expression; far from clinical utility |
| Population Reach | 5 | MM population |
| Implementation Speed | 2 | Discovery stage only |
| Evidence Strength | 3 | n=16 patients; RT-qPCR + IHC; no survival analysis; no external validation |
Main limitation: Critically small sample; no functional studies; no survival data; single-center
Evidence Maturity (revised): Validated → Exploratory (n=16 is insufficient for "Validated" designation regardless of statistical significance)
Article 16 — Extracavitary PEL in HIV-negative patient (PMID 42923817)
Case report | T1: Hematologic malignancies | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Expands phenotypic spectrum of a rare lymphoma; CD10+ immunophenotype in extracavitary HHV-8+ PEL is a genuine diagnostic pearl |
| Clinical Relevance | 4 | Educational value for hematopathologists; does not change treatment |
| Population Reach | 2 | Extremely rare; highly specialist interest |
| Implementation Speed | 5 | Diagnostic awareness is immediately applicable |
| Evidence Strength | 2 | Single case report; lowest possible evidence level |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 17 — Urinary biomarkers for urothelial carcinoma (PMID 42923287)
Narrative review | T3: Early cancer detection | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Multi-omics urine panels for UC are an active field; the triage framing (reduce cystoscopies, not replace) is clinically sensible |
| Clinical Relevance | 6 | Cystoscopy burden is significant; >90% sensitivity panels could meaningfully reduce invasive surveillance if validated prospectively |
| Population Reach | 7 | UC is the 4th most common cancer in men (~81,000 new US cases/year); surveillance-intensive disease |
| Implementation Speed | 3 | High sensitivity figures require external validation in clinical practice; regulatory approval needed |
| Evidence Strength | 3 | Narrative review; performance figures drawn from selected prospective cohorts but not meta-analyzed |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 18 — Salivary biomarkers in oral squamous cell carcinoma (PMID 42923286)
Narrative review | T3: Early cancer detection | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Saliva-tumor microenvironment linkage is emerging; the immunotherapy response prediction angle is relatively novel |
| Clinical Relevance | 5 | Point-of-care applicability is the key value; near-term feasibility for low-resource settings |
| Population Reach | 6 | OSCC is rising globally; especially in Asia and SSA; tobacco/alcohol-related risk |
| Implementation Speed | 3 | No clinical-grade validated assays yet; regulatory pathway not defined |
| Evidence Strength | 2 | Narrative review; no primary data; medium classification confidence |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 19 — Exhaled breath VOCs for lung cancer screening (preprint) (PMID 42922703)
Multicenter pilot, preprint | T3: Early cancer detection | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Truly non-invasive breath-based cancer screening is conceptually exciting; multicenter design is unusual for this stage |
| Clinical Relevance | 4 | Preprint; no peer review; sensitivity/specificity not reported in key_finding; pilot scale limits clinical inference |
| Population Reach | 8 | Lung cancer is the deadliest cancer globally (~1.8 million deaths/year); non-invasive screening tool with universal applicability would be transformative |
| Implementation Speed | 2 | Preprint, pilot, no validated assay, no regulatory pathway — 7–10+ years minimum |
| Evidence Strength | 3 | Preprint cap applies (≤7): low classification confidence further constrains; pilot scale; no peer review |
Main limitation: Preprint status; pilot scale; low classification confidence; no sensitivity/specificity data reported; case-control design may overestimate discrimination
Evidence Maturity (revised): Exploratory ✓ (confirmed); ⚠️ PREPRINT — treat with extra caution
Article 20 — AI in medical imaging: foundations and challenges (PMID 42923799)
Narrative review | T4: AI diagnostics | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | State-of-the-field synthesis; the field overview is comprehensive but adds little new to expert readers |
| Clinical Relevance | 5 | Barrier identification (regulatory, interpretability, liability) is useful for implementation planning |
| Population Reach | 8 | AI in medical imaging is cross-disease; impacts virtually all specialties |
| Implementation Speed | 3 | Review itself does not accelerate adoption; describes barriers to adoption |
| Evidence Strength | 2 | Narrative review only |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 21 — AI in breast imaging and screening (PMID 42921358)
Narrative review | T4: AI diagnostics + T3: Early cancer detection | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Synthesizes landmark 2023–2026 RCT results; not itself generating new evidence but curating a rapidly evolving evidentiary base |
| Clinical Relevance | 7 | AI-supported mammography with 10–29% detection improvement and 31–64% radiologist workload reduction are practice-relevant figures; directly applicable to radiology departments |
| Population Reach | 9 | Breast cancer screening is one of the most widely deployed cancer interventions globally; millions of women screened annually |
| Implementation Speed | 5 | AI mammography systems are CE/FDA cleared in several markets; adoption is underway but uneven; mortality data gap remains a caution |
| Evidence Strength | 4 | Narrative review of RCTs and prospective studies — the underlying data are strong but the review itself is not systematic |
Equity implications: Explicitly noted: evidence skewed toward high-income, non-diverse populations — AI systems may perform differently in diverse populations
Evidence Maturity (revised): Exploratory ✓ (narrative review of underlying validated studies; does not itself constitute validated evidence)
Article 22 — AI for periodontal pocket severity from radiographs (PMID 42923715)
Retrospective validation | T4: AI diagnostics | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI periodontal grading from radiographs is a crowded space; 13,809 teeth and full-mouth radiograph methodology adds scale |
| Clinical Relevance | 5 | Useful dental adjunct; moderate correlation with probing depth limits use as surrogate |
| Population Reach | 6 | Periodontal disease affects ~50% of adults globally |
| Implementation Speed | 5 | Retrospective validation; prospective clinical validation needed before deployment |
| Evidence Strength | 5 | Large dataset (655 cases, 13,809 teeth); retrospective; moderate correlation (r=0.502) suggests useful but imperfect tool |
Key quantitative result: 90.48% classification accuracy; AUC 0.767–0.789; r=0.502 with max probing depth
Evidence Maturity (revised): Validated ✓ (confirmed; technical validation complete, clinical workflow integration pending)
Article 23 — GSTP1 and prostate cancer senescence (PMID 42923011)
Bioinformatics + experimental validation | T5: Precision oncology | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | GSTP1 is known in prostate cancer; the SASP mechanistic reframing adds conceptual novelty; senescence biology linkage is timely |
| Clinical Relevance | 3 | Cell line + bioinformatics; no patient cohort validation |
| Population Reach | 6 | Prostate cancer is the most common male cancer; GSTP1 is broadly expressed |
| Implementation Speed | 2 | Discovery only |
| Evidence Strength | 3 | Mixed-species model; bioinformatics + cell lines; no clinical validation; medium classification confidence |
Evidence Maturity (revised): Validated → Exploratory (cell line/bioinformatics does not constitute clinical validation)
Article 24 — Obesity-estrogen-polyamine axis in endometrial cancer (PMID 42922976)
Narrative review | T5: Precision oncology | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Polyamine pathway as the mechanistic bridge between obesity and endometrial cancer is a relatively underexplored and integrative framing |
| Clinical Relevance | 4 | No clinical data; preclinical targets only |
| Population Reach | 7 | Endometrial cancer incidence rising with obesity epidemic; affects hundreds of thousands globally |
| Implementation Speed | 2 | Entirely preclinical; ornithine decarboxylase inhibitors are available but not validated in this context |
| Evidence Strength | 2 | Narrative review; no primary data; medium classification confidence |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 25 — Histone modifications in laryngeal squamous cell carcinoma (PMID 42923756)
Systematic review | T5: Precision oncology | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Histone lactylation and succinylation in LSCC are relatively novel; EZH2 + ICI combination rationale is clinically current |
| Clinical Relevance | 5 | Preclinical evidence only; clinical trials needed; relevant to a cancer with limited precision oncology options |
| Population Reach | 4 | Laryngeal cancer is not rare (~180,000 new cases/year globally) but smaller than major cancers |
| Implementation Speed | 3 | Preclinical evidence only; regulatory pathway undefined |
| Evidence Strength | 4 | Systematic review methodology but source studies are predominantly preclinical; functional clinical data absent |
Evidence Maturity (revised): Validated ✓ (confirmed, but limited to preclinical model evidence)
Article 26 — Ferroptosis and radio-immunosensitization (PMID 42923766)
Narrative review | T6: Novel therapeutics | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Mechanistic framework linking RT-induced lipid peroxidation → ferroptosis → ICI sensitization is conceptually innovative and timely |
| Clinical Relevance | 3 | No clinical validation; no biomarkers; immune cell ferroptosis paradox unresolved |
| Population Reach | 7 | ICI resistance affects millions of cancer patients across tumor types |
| Implementation Speed | 2 | Preclinical only; no clinical-grade ferroptosis inducers validated |
| Evidence Strength | 2 | Narrative review; preclinical evidence base only |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 27 — Triglyceride-glucose index and coronary artery calcification (PMID 42923171)
Longitudinal cohort | T7: Cardiovascular-metabolic | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | TyG index as a CV risk marker is well-established; longitudinal CAC progression association is an incremental but useful addition |
| Clinical Relevance | 6 | TyG index is easily calculable from routine labs; if adopted, could improve patient selection for early SGLT2i/GLP-1 intervention |
| Population Reach | 8 | Insulin resistance and cardiovascular disease are globally prevalent |
| Implementation Speed | 7 | No new testing required — TyG index computable from existing lab values; adoption is immediate if clinical guidelines endorse |
| Evidence Strength | 6 | Longitudinal design strengthens causal inference; medium classification confidence noted; sample size and follow-up duration not specified in metadata |
Key quantitative result: Higher TyG independently associated with faster CAC progression (direction/magnitude not quantified in key_finding)
Main limitation: Sample size and follow-up period unknown from available metadata; medium classification confidence
Evidence Maturity (revised): Validated ✓ (confirmed; longitudinal design appropriate)
Article 28 — Redox signaling and immunosenescence (PMID 42921489)
Narrative review | T8: Aging | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ROS/redox-immunosenescence link is recognized; the "signaling fidelity" framing adds conceptual precision |
| Clinical Relevance | 3 | No clinical data; targets proposed but not validated clinically |
| Population Reach | 8 | Aging and immune dysfunction affect all aging humans |
| Implementation Speed | 2 | Mechanistic review; no clinical translation pathway defined |
| Evidence Strength | 2 | Narrative review; no primary data; medium classification confidence |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 29 — Gut microbiota in Alzheimer's disease and healthy aging (PMID 42925463)
Narrative review | T8: Aging | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Gut-brain axis in AD is a well-populated research area; no new mechanistic contribution |
| Clinical Relevance | 4 | Probiotic evidence is preliminary and RCT data sparse |
| Population Reach | 9 | Alzheimer's affects 50+ million globally; rising with aging populations |
| Implementation Speed | 3 | No clinical-grade probiotic interventions validated for AD |
| Evidence Strength | 2 | Narrative review; no primary data |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 30 — Exposomic determinants in heart failure in older adults (PMID 42925369)
Narrative review | T8: Aging | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Exposome as a unified risk framework for HF in older adults is a relatively novel framing; noise pollution and circadian disruption as HF determinants are emerging |
| Clinical Relevance | 4 | Conceptually important but no actionable clinical tool generated; environmental exposures are not easily modified individually |
| Population Reach | 8 | HF affects 64 million globally; aging populations most at risk |
| Implementation Speed | 2 | Exposome assessment tools not standardized; policy-level interventions required |
| Evidence Strength | 2 | Narrative review; medium classification confidence |
Evidence Maturity (revised): Exploratory ✓ (confirmed)
Article 31 — Family screening in Wilson disease (PMID 42926038)
Cohort/observational | T9: Rare diseases | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Family cascade screening concept for Wilson disease is established; implementation data adds to the evidence base |
| Clinical Relevance | 7 | Identifies presymptomatic cases who can receive copper chelation before irreversible damage — high per-patient clinical impact |
| Population Reach | 3 | Wilson disease prevalence ~1/30,000; extremely rare |
| Implementation Speed | 6 | Screening protocols are available now; barriers are coordination and awareness |
| Evidence Strength | 5 | Cohort/observational design; medium classification confidence; sample size not specified |
Equity implications: Geographic access disparities in cascade screening are the central implementation barrier — affects equity directly
Evidence Maturity (revised): Validated ✓ (confirmed)
Article 32 — HNRNPU-related disorder: caregiver experiences (PMID 42922377)
Qualitative study | T9: Rare diseases | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Caregiver qualitative studies in ultra-rare epileptic encephalopathies are uncommon; the diagnostic odyssey and support gap data are useful |
| Clinical Relevance | 4 | No therapeutic implications; informs support service and genetic counseling design |
| Population Reach | 2 | Extremely rare (de novo HNRNPU variants estimated in hundreds globally) |
| Implementation Speed | 4 | Awareness and support service improvements can follow from findings |
| Evidence Strength | 4 | Qualitative design appropriate for its research question; medium classification confidence; no sample size in metadata |
Equity implications: Diagnostic odyssey is severe; families without access to tertiary genetics centers face longest delays
Evidence Maturity (revised): Validated ✓ (confirmed; appropriate design for question)
Article 33 — HPV testing + LBC after negative colposcopy (unsolicited) (PMID 42924372)
Multicenter clinical study | T3: Early cancer detection | triage_score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Post-colposcopy surveillance optimization is a practical and underresearched niche; combined testing approach is protocol-relevant |
| Clinical Relevance | 6 | High NPV from combined testing directly informs post-colposcopy discharge vs. continued surveillance decisions |
| Population Reach | 8 | Cervical cancer remains a leading cancer in women globally; surveillance burden is high post-colposcopy |
| Implementation Speed | 6 | Both HPV testing and LBC are available everywhere; protocol change is feasible |
| Evidence Strength | 5 | Multicenter design is a strength; medium classification confidence; detection rates not fully quantified in key_finding |
Equity implications: Cervical cancer disproportionately affects women in LMICs; Brazilian study population adds some generalizability beyond high-income settings
Evidence Maturity (revised): Validated ✓ (confirmed)